Sponsors developing drugs for rare diseases should pursue several strategies to assess safety, including gathering robust natural history data and using a concurrent comparator arm, the US FDA advises in a new draft guidance.
The draft guidance, "Rare Diseases: Common Issues in Drug Development," revises and replaces a draft by the same name...